Inhibrx Biosciences, Inc.INBXNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank78
3Y CAGR+0.9%
5Y CAGR+9.0%
Year-over-Year Change
Research and development spending
3Y CAGR
+0.9%/yr
vs +34.7%/yr prior
5Y CAGR
+9.0%/yr
Recent deceleration
Acceleration
-33.9pp
Decelerating
Percentile
P78
Within normal range
vs 5Y Ago
1.5x
Solid growth
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $113.03M | -44.5% |
| 2024 | $203.74M | +6.9% |
| 2023 | $190.65M | +73.0% |
| 2022 | $110.19M | +54.2% |
| 2021 | $71.44M | -2.8% |
| 2020 | $73.50M | +53.4% |
| 2019 | $47.91M | +43.2% |
| 2018 | $33.45M | +31.1% |
| 2017 | $25.51M | +50.1% |
| 2016 | $16.99M | - |